LeMaitre Vascular, Inc. filings document a Nasdaq-listed medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Recent Form 8-K reports furnish quarterly operating and financial results, dividend-related updates, and related press release exhibits.
Proxy and governance filings cover board structure, director elections, executive compensation, advisory say-on-pay matters, and shareholder voting results. The filings also identify the company’s common stock, par value, Nasdaq Global Market listing under LMAT, and related public-company disclosure controls.
LeMaitre Vascular, Inc. Schedule 13G/A shows George W. LeMaitre beneficially owns 1,465,235 shares of common stock, equal to 6.4% of the class. The filing states there were 22,847,733 shares outstanding as of March 31, 2026. The reported amount includes 6,847 shares subject to options exercisable within 60 days of March 31, 2026.
LeMaitre Vascular Chairman and CEO George W. LeMaitre reported open-market sales of company stock. On May 7 he sold 18,600 shares of common stock at a weighted average price of $107.6351 per share, and on May 8 he sold 27,881 shares at a weighted average price of $108.6905 per share.
After these direct sales, he continued to hold 1,430,019 shares directly. The filing also shows 33,400 shares held indirectly by the “LeMaitre Irrevocable Life Insurance Trust of 2025,” for the benefit of his children, where he disclaims beneficial ownership except for any pecuniary interest.
LeMaitre Vascular Senior Vice President of Operations Trent G. Kamke sold 2,928 shares of Common Stock in an open-market transaction on May 8, 2026. The weighted average sale price was $106.9969 per share, with trades ranging from $105.32 to $107.46. Following this sale, Kamke directly holds 3,749 shares.
LEMAITRE VASCULAR director Bridget A. Ross reported an exercise-and-sale transaction in company stock. On May 7, 2026, she exercised stock options to acquire a total of 5,044 shares of Common Stock, including 1,600 shares at an exercise price of $47.19 per share and 3,444 shares at $48.60 per share.
On the same date, she completed an open‑market sale of 5,044 Common Stock shares at a weighted average price of $111.0956 per share, executed in multiple trades ranging from $111.00 to $111.30. Following these transactions, she directly owns 3,942 Common Stock shares, and the reported options tied to these exercises are fully vested and, after exercise, no longer outstanding.
LeMaitre Vascular director Lawrence J. Jasinski reported an exercise-and-sell transaction in company stock. On May 7, 2026, he sold 3,943 shares of common stock in an open-market sale at $110.00 per share, leaving him with 4,714 directly held shares afterward.
On the same date, he exercised stock options to acquire a total of 2,858 common shares at exercise prices of $101.12, $54.65, and $47.19 per share. Related option entries show remaining option positions in multiple grants following these exercises. Overall, the filing reflects a combination of option exercises and a net sale of shares.
LMAT filing reports restricted common stock vesting events and two Rule 144 sales by Trent G. Kamke. The filing lists vested restricted shares dated 03/14/2025 and 03/03/2025, and two reported dispositions on 02/27/2026 and 03/11/2026.
LMAT Form 144 notice reports a proposed sale of common stock by Morgan Stanley Smith Barney LLC Executive Financial Services, dated 05/07/2026.
The filing lists a Stock Option Exercise for 2,858 shares on 05/07/2026 and multiple equity award entries: 208, 203, 158, 140, 173, and 203 shares tied to grant or vesting dates in 12/2025 and 02/26/2026.
LeMaitre Vascular, Inc. reported solid first‑quarter 2026 growth with higher sales, margins, and earnings. Net sales rose to $66.6 million, up 11% from 2025, driven by grafts, valvulotomes, and shunts across all regions. Gross profit increased to $48.4 million and gross margin improved to 72.7%, helped by price increases, manufacturing efficiencies, and a more profitable product mix.
Net income grew to $15.7 million, up from $11.0 million, with diluted EPS at $0.68. The company generated $15.1 million of operating cash flow, ending the quarter with $26.9 million in cash and $340.4 million in short‑term marketable securities, alongside $172.5 million of 2.50% convertible senior notes due 2030.
LeMaitre increased its quarterly dividend to $0.25 per share and authorized a $100 million share repurchase program, while continuing to invest in global sales expansion, ERP implementation, and facility leases. Biologics represented 53% of sales, and international markets contributed 44% of net sales, aided by a weaker U.S. dollar and recent regulatory approvals.
LeMaitre Vascular, Inc. reported strong preliminary Q1 2026 results with net sales of $66.6M, up from $59.9M, driven by 11% sales growth and broad strength across products and regions. Artegraft sales grew 36% worldwide, while grafts, valvulotomes, and carotid shunts each set record sales.
Gross margin reached 72.7%, up 350 basis points, and operating income rose to roughly $17.8M, a 41% increase. Diluted EPS grew 42% in Q1. Management’s guidance implies full-year 2026 sales growth of 12% and adjusted EPS growth of 26%, with Q2 sales expected around $71.5M at the midpoint.
The board approved a quarterly dividend of $0.25 per share payable on June 4, 2026, and authorized a share repurchase program of up to $100M through February 18, 2027. The company also highlighted non-GAAP metrics such as adjusted EBITDA and organic sales growth.